HomeICPT • BMV
add
Intercept Pharmaceuticals Ord Shs
Nakaraang pagsara
$329.00
Sakop ng taon
$329.00 - $329.00
Market cap
794.36M USD
P/E ratio
-
Dividend yield
-
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2023info | Y/Y na pagbabago |
|---|---|---|
Kita | 88.79M | 14.44% |
Gastos sa pagpapatakbo | 86.95M | -0.41% |
Net na kita | -2.79M | -101.04% |
Net profit margin | -3.14 | -100.91% |
Kita sa bawat share | 0.08 | -99.20% |
EBITDA | 1.74M | 117.27% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2023info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 322.71M | -34.25% |
Kabuuang asset | 393.16M | -29.72% |
Kabuuang sagutin | 321.32M | -28.87% |
Kabuuang equity | 71.84M | — |
Natitirang share | 41.83M | — |
Presyo para makapag-book | 191.28 | — |
Return on assets | 0.93% | — |
Return on capital | 1.18% | — |
Cash Flow
Net change in cash
| (USD) | Set 2023info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -2.79M | -101.04% |
Cash mula sa mga operasyon | 16.69M | 200.59% |
Cash mula sa pag-invest | 59.77M | -81.97% |
Cash mula sa financing | -110.00M | 57.27% |
Net change in cash | -33.70M | -163.39% |
Malayang cash flow | 16.70M | 211.23% |
Tungkol
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. Wikipedia
CEO
Itinatag
2002
Website
Mga Empleyado
341
